Aurigene, Alveus advance obesity pipeline with ALV-200 candidate nomination

The collaboration combines Alveus’ expertise in metabolic biology and therapeutic strategy with Aurigene’s integrated discovery capabilities

Experts advocate holistic Semaglutide use as therapy goes off patent in India

They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market

Semaglutide not a “Quick Fix”: Top docs urge holistic approach as drug goes off patent in India

They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.

Zydus launches affordable Semaglutide in India after patent expiry

Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders

Zydus and Torrent Pharma to co-market Semaglutide injection in India

Zydus has developed an innovative formulation of Semaglutide Injection in a prefilled cartridge administered using a reusable patient-friendly pen device

Zydus, Lupin join forces to expand access to semaglutide in India

The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus

FDA greenlights Biocon’s Liraglutide for chronic weight management

Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management

Novo Nordisk’s "Triple G" drug UBT251 triggers nearly 20% weight loss in 24 weeks

UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies

Moderna teams up with Recordati to commercialize rare disease therapy

Alveus Therapeutics launches with $159.8m Series A to advance next-gen obesity drugs

ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism